Richard Aplenc MD

PubMed

• DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children'...
  Vivek M Shastri, Lata Chauhan, Mohammed Gbadamosi, Todd A Alonzo, Yi-Cheng Wang
  Clinical Cancer Research. 2025-03-03
• 1 citations
  Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy.
  Barbara D Friedes, Amanda M DiNofia, Emma Iannone, Yimei Li, Susan R Rheingold
  Blood Advances. 2025-01-28
• 3 citations
  Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.
  Julie K Jadlowsky, Elizabeth O Hexner, Amy Marshall, Stephan A Grupp, Noelle V Frey
  Nature Medicine. 2025-01-20

Abstracts/Posters

• Disparities in Barriers and Facilitators of Acute Leukemia Diagnosis in Young Patients
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report ...
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational Profile
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Chi...
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a ChildrenÍs Onc...
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN)
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS)
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Delays in Therapy Do Not Impact Survival in Childhood Acute Lymphoblastic Leukemia: A Report from the Learn Consortium
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient ...
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantatio...
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long Non-Coding RNAs (lncRNAs) Are Highly Associated with Disease Characteristics and Outcome in Pediatric Acute Myeloid Leukemia _ a COG and Tpaml Study
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene _ a COG/Tpaml Study
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the ChildrenÍs Oncology Group
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Pa...
  Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A re... 
  2019 ASCO Annual Meeting - 6/1/2019
• Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pediatric Patient-Reported Symptom Tracking in Oncology (Pedi-PReSTO): A Feasibility Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Comparing the Liver Function of Children with Acute Lymphoblastic Leukemia (ALL) Receiving Standard or High Intensity Treatment during the Interim Maintenance I Phase ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all